Table 2.
Clinical and laboratory features at MAHA diagnosis and association with 4-week survival
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| Factors | N (%) | OR | 95% IC | p value | OR | 95% IC | p value |
| PS at MAHA diagnosis | |||||||
| PS 1–2 | 30 (55.6%) | 1.0 | 0.003 | 1.0 | 0.01 | ||
| PS 3–4 | 24 (44.4%) | 6.0 | [1.8; 19.8] | 7.0 | [1.6; 31.8] | ||
| Clinical bleeding | |||||||
| Yes | 9 (16.7%) | NS | NS | ||||
| No | 45 (83.3%) | ||||||
| Neurological symptoms | |||||||
| Yes | 15 (28.3%) | NS | NS | ||||
| No | 38 (71.7%) | ||||||
| NA | 1 | ||||||
| Dyspnoea | |||||||
| Yes | 11 (20.8%) | NS | NS | ||||
| No | 42 (79.2%) | ||||||
| NA | 1 | ||||||
| Metastatic sites | |||||||
| < 3 | 25 (46.3%) | NS | NS | ||||
| ≥ 3 | 29 (53.7%) | ||||||
| Metastasis | |||||||
| Bone marrowa | 11 (78.5%) | ||||||
| Bone | 44 (81.5%) | ||||||
| Lung | 8 (14.8%) | NS | NS | ||||
| Liver | 35 (64.8%) | ||||||
| Otherb | 24 (44.4%) | ||||||
| Number of prior treatment lines | |||||||
| ≤ 1 | 26 (48.1%) | 1.0 | 0.06 | NS | |||
| > 1 | 28 (51.9%) | 2.9 | [1.0; 8.7] | ||||
| Platelets | |||||||
| < 50 G/L | 29 (53.7%) | NS | NS | ||||
| ≥ 50 G/L | 25 (46.3%) | ||||||
| Haemoglobin | |||||||
| < 8 g/L | 26 (48.1%) | 4.0 | [1.3; 12.5] | 0.02 | 3.7 | [0.9; 16.7] | 0.08 |
| ≥ 8 g/L | 28 (51.9%) | 1.0 | 1.0 | ||||
| Schistocytes | |||||||
| > 5.0% | 10 (25.0%) | NS | NS | ||||
| 0.5–5.0% | 30 (75.0%) | ||||||
| NA | 14 | ||||||
| Erythroblastemia | |||||||
| Yes | 40 (85.1%) | NS | NS | ||||
| No | 7 (14.9%) | ||||||
| NA | 7 | ||||||
| Myelemia | |||||||
| Yes | 38 (90.5%) | NS | NS | ||||
| No | 4 (9.5%) | ||||||
| NA | 12 | ||||||
| Prothrombin time | |||||||
| < 50% | 8 (16.0%) | 4.5 | [0.9; 25.0] | 0.07 | 9.1 | [1.2; 50.0] | 0.03 |
| ≥ 50% | 42 (84.0%) | 1.0 | 1.0 | ||||
| NA | 4 | ||||||
| Fibrinogen | |||||||
| ≤ 2 g/L | 15 (34.9) | NS | NS | ||||
| > 2 g/L | 28 (65.1) | ||||||
| NA | 11 | ||||||
| Glomerular filtration eate | |||||||
| > 60 mL/min | 25 (65.8%) | NS | NS | ||||
| 30–60 mL/min | 9 (23.7%) | NS | |||||
| < 30 mL/min | 4 (10.5%) | NS | |||||
| NA | 16 | ||||||
| Total bilirubin level | |||||||
| < 1.24 mg/dL | 16 (30.8%) | 1.0 | 0.007 | 1.0 | |||
| ≥ 1.24 mg/dL | 36 (69.2%) | 7.3 | [1.8; 30.6] | 6.9 | [1.1; 42.6] | 0.04 | |
| NA | 2 | ||||||
| Pronopall scorec | |||||||
| Short survival | 12 (31.6%) | 3.7 | [0.8; 16.8] | 0.09 | |||
| Intermediate/long survival | 26 (68.4%) | 1.0 | NS | ||||
| NA | 16 | ||||||
NA not available, OR odds ratio, NS non-significant
aOnly 14 patients had a bone marrow examination (myelogram or bone marrow biopsy) at the time of BC-MAHA diagnosis
bOthers metastatic sites: cerebral, carcinomatous meningitis, node involvement
cThe pronopall score for early death among oncology patients was calculated according to Barbot et al., J Clin Oncol 2008, missing data being imputed